var data={"title":"Propafenone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Propafenone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6853?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=propafenone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Propafenone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709354\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non&ndash;life-threatening ventricular arrhythmias who had a myocardial infarction (MI) more than 6 days but less than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide (class IC antiarrhythmics) compared with that seen in patients assigned to placebo (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The applicability of the CAST results to other populations (eg, those without recent MI) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, generally avoid antiarrhythmic agents in patients with non&ndash;life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214329\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rythmol SR;</li>\n      <li>Rythmol [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214330\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Propafenone;</li>\n      <li>Mylan-Propafenone;</li>\n      <li>PMS-Propafenone;</li>\n      <li>Rythmol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214373\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class Ic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214334\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients who exhibit significant widening of QRS complex or second- or third-degree AV block may need dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (to prevent recurrence):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release capsule:</i> Initial: 225 mg every 12 hours; dosage increase may be made at a minimum of 5-day intervals; may increase to 325 mg every 12 hours; if further increase is necessary, may increase to 425 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release tablet:</i> Initial: 150 mg every 8 hours; dosage increase may be made at minimum of 3- to 4-day intervals, may increase to 225 mg every 8 hours; if further increase is necessary, may increase to 300 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal supraventricular tachycardia  (to prevent recurrence), ventricular arrhythmias:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i></i>Oral: <i>Immediate release tablet:</i> Initial: 150 mg every 8 hours; dosage increase may be made at minimum of 3- to 4-day intervals, may increase to 225 mg every 8 hours; if further increase is necessary, may increase to 300 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i> Supraventricular tachycardia: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immediate release:</i> Initial: 150 mg every 8 hours; maximum maintenance dose: 300 mg every 8 hours (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release:</i> Initial: 225 mg every 12 hours; maximum maintenance dose: 425 mg every 12 hours (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal atrial fibrillation, pharmacologic cardioversion (off-label use):</b> Oral:<b> Note:</b> May be used on an outpatient basis (&ldquo;Pill-in-the-pocket&rdquo;). An initial inpatient cardioversion trial should have been successful before sending patient home on this approach. Patient must be taking an AV nodal-blocking agent (eg, beta-blocker, nondihydropyridine calcium channel blocker) prior to initiation of antiarrhythmic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release tablet:</i> 450 mg (weight &lt;70 kg), 600 mg (weight &ge;70 kg). May not repeat in &le;24 hours (Alboni, 2004; AHA/ACC/HRS [January, 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214335\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13657360\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">There are no dosage adjustments provided in the manufacturer's labeling; however, 50% of propafenone metabolites (some active) are excreted in the urine; some data suggest that no dosage adjustment is necessary (Burgess, 1989; Fromm, 1994); however, use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Hemodialysis/CVVH: Minimally dialyzable (Burgess, 1989; Seto, 1999); supplemental dose not necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214336\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer&rsquo;s labeling; however, dosage reduction should be considered as drug undergoes hepatic metabolism. Alternatively, in patients with mild to moderate impairment, the following dosing recommendations have been made: Initial: 150 mg once daily; if necessary, may increase dosage by 150 mg/day in divided doses (eg, twice daily, three times daily) at a minimum of 4-day intervals up to maximum of 300 mg every 12 hours (Rythmol Canadian product labeling 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214307\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rythmol SR: 225 mg, 325 mg, 425 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 225 mg, 325 mg, 425 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rythmol: 150 mg [DSC], 225 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 225 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214292\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29118606\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rythmol: 150 mg, 300 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214311\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Capsules should be swallowed whole; do not crush or chew; may be taken without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The Canadian labeling recommends the tablet be swallowed whole with liquid and to be administered with food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214310\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of life-threatening ventricular arrhythmias; to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) or paroxysmal supraventricular tachycardia (PSVT) in patients with disabling symptoms without structural heart disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b> Due to safety risks, propafenone should be reserved for use in patients with symptomatic supraventricular tachycardias (SVTs) (atrioventricular nodal reentrant tachycardia [AVNRT], atrioventricular reentrant tachycardia [AVRT], focal atrial tachycardia [AT]) in patients without structural or ischemic heart disease who are not candidates for, or prefer not to undergo catheter ablation and in whom other therapies have failed or are contraindicated (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Extended release capsule: Prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744558\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Paroxysmal atrial fibrillation (pharmacological cardioversion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214299\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Unusual taste (3% to 23%), dizziness (4% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;11%), vomiting (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (2% to 10%; new or worsened; proarrhythmic effect), angina pectoris (2% to 5%), cardiac failure (1% to 4%), first degree atrioventricular block (1% to 3%), palpitations (1% to 3%), ventricular tachycardia (1% to 3%), bradycardia (1% to 2%), chest pain (1% to 2%), widened QRS complex on ECG (1% to 2%), syncope (1% to 2%), ventricular premature contractions (1% to 2%), atrial fibrillation (1%), bundle branch block (&le;1%), edema (&le;1%), cardiac conduction delay (&le;1%; intraventricular), hypotension (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (2% to 6%), headache (2% to 5%), ataxia (&le;2%), insomnia (&le;2%), anxiety (1% to 2%), drowsiness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1% to 3%), diaphoresis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (2% to 7%), diarrhea (1% to 3%), dyspepsia (1% to 3%), abdominal pain (1% to 2%), anorexia (1% to 2%), xerostomia (1% to 2%), flatulence (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1% to 2%), arthralgia (&le;1%), tremor (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, agranulocytosis, alopecia, altered sense of smell, amnesia, anemia, apnea, asystole, atrioventricular block (second or third degree), atrioventricular dissociation, cardiac failure, cholestasis, coma, confusion, depression, eye irritation, flushing, gastroenteritis, granulocytopenia, hepatitis, hyperglycemia, hyponatremia, impotence, increased serum transaminases, leukopenia, lupus erythematosus, mania, muscle cramps, myasthenia, nephrotic syndrome, numbness, pain, paresthesia, peripheral neuropathy, positive ANA titer, prolongation P-R interval on ECG, prolonged bleeding time, pruritus, psychosis, purpura, renal failure, seizure, SIADH (syndrome of inappropriate antidiuretic hormone secretion), sinoatrial arrest, sinus node dysfunction, speech disturbance, thrombocytopenia, tinnitus, torsades de pointes, ventricular fibrillation, vertigo, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214314\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to propafenone or any component of the formulation; sinoatrial, AV, and intraventricular disorders of impulse generation and/or conduction (except in patients with a functioning artificial pacemaker); Brugada syndrome, sinus bradycardia; cardiogenic shock; uncompensated cardiac failure; marked hypotension; bronchospastic disorders or severe obstructive pulmonary disease; uncorrected electrolyte abnormalities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): MI within past 3 months; severe hepatic impairment; myasthenia gravis; concurrent use with ritonavir</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214296\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Agranulocytosis: Agranulocytosis has been reported; generally occurring within the first 2 months of therapy. Upon therapy discontinuation, WBC usually normalized by 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness, fatigue, blurred vision; caution patients about performing dangerous tasks (eg, driving, operating machinery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction disturbances: Slows atrioventricular conduction, potentially leading to first degree AV block; degree of PR interval prolongation and increased QRS duration are dose and concentration related. Avoid in patients with conduction disturbances (unless functioning pacemaker present).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatic abnormalities (including fulminant hepatitis and fatalities) have been reported; toxicity appeared due to hepatocellular injury and/or cholestasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: Can cause life-threatening drug-induced arrhythmias, including ventricular fibrillation, ventricular tachycardia, asystole, and torsade de pointes (Hii, 1991). The manufacturer notes that propafenone may increase the QT interval; however, due to QRS prolongation; changes in the QT interval are difficult to interpret. In an evaluation of propafenone (450 mg/day) in healthy individuals compared to other selected antiarrhythmic agents, propafenone did not affect repolarization time (eg, QT, QTc, JT, JTc) only depolarization time (ie, QRS interval) (Sarubbi, 1998).  Monitor for proarrhythmic effects, and when necessary, adjust dose to prevent QT<sub>c</sub> prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Brugada syndrome: Initiation of propafenone may unmask Brugada syndrome; obtain ECG after treatment initiation and discontinue if ECG indicative of Brugada syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Use is contraindicated in patients with uncorrected electrolyte abnormalities. Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Avoid use in patients with HF; similar agents have been shown to increase mortality in this population; may precipitate or exacerbate condition (Lindenfeld, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lupus erythematosus: Positive ANA titers have been reported with use. Titers have decreased with and without therapy discontinuation. Positive titers have not usually been associated with clinical symptoms, although at least one case of drug induced lupus erythematosus has been reported. Consider therapy discontinuation in symptomatic patients with positive ANA titers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: Propafenone use may be considered in patients with obstructive lung disease who do not have bronchospasm (AHA/ACC/HRS [January, 2014]). Use in patients with bronchospastic disease or severe obstructive lung disease is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAST trial:<b> [US Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.</b> An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pacemakers: May alter pacing and sensing thresholds of artificial pacemakers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214366\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP2D6 (weak), P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214301\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9821&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class Ia): Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).  Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).  Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Propafenone. Management: Canadian labeling recommends avoiding this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Propafenone may increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity. <b> Exceptions: </b>Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Propafenone may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: Propafenone may enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Propafenone. Management: Concurrent use of ritonavir-boosted fosamprenavir with propafenone is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with propafenone is not specifically contraindicated but should only be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: May increase the serum concentration of Propafenone. Management: Monitor clinical response to propafenone closely.  Dose adjustment may be necessary.  Canadian mirabegron labeling recommends restricting the maximum adult mirabegron dose to 25 mg/day in patients receiving propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol: Propafenone may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May enhance the arrhythmogenic effect of Propafenone. Saquinavir may increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May enhance the QTc-prolonging effect of Propafenone. Sertraline may increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May enhance the adverse/toxic effect of Propafenone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Propafenone may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venlafaxine: Propafenone may increase the serum concentration of Venlafaxine.  Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/dose increase. Conversely, monitor for decreased venlafaxine levels with profapenone discontinuation/dose decrease.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Propafenone may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214327\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Administration of food with single-dose propafenone increased propafenone serum concentrations and bioavailability; however, with multidose administration, propafenone bioavailability was not significantly different between fed and fasted states. Management: Administer without regard to meals. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Propafenone serum concentrations may be increased with concomitant use of grapefruit juice. Management: Avoid concomitant use of grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214303\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214317\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Propafenone and its metabolite cross the placenta and can be detected in the newborn (Libardoni 1991). Guidelines are available for use during pregnancy (ESG [Regitz-Zagrosek 2011]). Propafenone may be used for the ongoing management of pregnant women with highly symptomatic SVT. The lowest effective dose is recommended; avoid use during the first trimester if possible (Page [ACC/AHA/HRS 2015]).Until more information is available, when treatment of AF or long term treatment of SVT  is needed in pregnant women, propafenone is generally reserved for use when other agents are not effective (ESG [Regitz-Zagrosek 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20619290\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Propafenone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214305\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, blood pressure, pulse (particularly at initiation of therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214295\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Propafenone is a class 1c antiarrhythmic agent which possesses local anesthetic properties, blocks the fast inward sodium current, and slows the rate of increase of the action potential. Prolongs conduction and refractoriness in all areas of the myocardium, with a slightly more pronounced effect on intraventricular conduction; it prolongs effective refractory period, reduces spontaneous automaticity and exhibits some beta-blockade activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214313\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Adults: 252 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 95% to alpha<sub>1</sub>-acid glycoprotein </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2D6, CYP3A4 and CYP1A2 to two active metabolites (5-hydroxypropafenone and N-depropylpropafenone) then ultimately to glucuronide or sulfate conjugates. Two genetically determined metabolism groups exist (extensive and poor metabolizers); 10% of Caucasians are poor metabolizers. Exhibits nonlinear pharmacokinetics; when dose is increased from 300-900 mg/day, serum concentrations increase tenfold; this nonlinearity is thought to be due to saturable first-pass effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release (IR): 150 mg: 3.4%; 300 mg: 10.6%; relative bioavailability of extended release (ER) capsule is less than IR tablet; the bioavailability of  an ER capsule regimen of  325 mg twice-daily regimen approximates an IR tablet regimen of 150 mg 3 times/day. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Extensive metabolizers: 2-10 hours; Poor metabolizers: 10-32 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IR: 3.5 hours; ER: 3-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1% unchanged; remainder as glucuronide or sulfate conjugates); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214316\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, 12-hour</b> (Propafenone HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">225 mg (60): $473.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (60): $599.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">425 mg (60): $599.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, 12-hour</b> (Rythmol SR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">225 mg (60): $876.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (60): $1,109.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">425 mg (60): $1,109.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Propafenone HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $163.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">225 mg (100): $232.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $296.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214319\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arythmol (GB, IE, MT);</li>\n      <li>Nistaken (MX);</li>\n      <li>Norfenon (MX);</li>\n      <li>Normorytmin (AR);</li>\n      <li>Profex (IL);</li>\n      <li>Pronon (JP);</li>\n      <li>Propafen (CO);</li>\n      <li>Propafenon Genericon (HR);</li>\n      <li>Propafenon Pharmavit (HU);</li>\n      <li>Propanorm (UA);</li>\n      <li>Prorynorm (LU);</li>\n      <li>Rhythmonorm (IN);</li>\n      <li>Ritmocor (CL);</li>\n      <li>Ritmonorm (BR, PY);</li>\n      <li>Rythmex (IL);</li>\n      <li>Rythmol (CO, FR, VN, ZA);</li>\n      <li>Rythmonorm (GR);</li>\n      <li>Rythmosin (BD);</li>\n      <li>Rytmocard (BG, PH);</li>\n      <li>Rytmol (UY);</li>\n      <li>Rytmonorm (AE, AU, BE, CH, CN, CY, CZ, DE, DK, EE, EG, ES, FI, HK, HN, HR, HU, ID, IT, JO, KR, KW, LB, LT, LU, LV, MY, NL, NZ, PE, PL, PT, QA, RU, SE, SG, SI, SK, TH, TR, TW, UA, VE);</li>\n      <li>Rytmonorma (AT);</li>\n      <li>Ryytmonorm (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15575054\"></a>Alboni P, Botto GL, Baldi N, et al, &quot;Outpatient Treatment of Recent-Onset Atrial Fibrillation With the &quot;Pill-in-the-Pocket&quot; Approach,&quot; <i>N Engl J Med</i>, 2004, 351(23):2384-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/15575054/pubmed\" target=\"_blank\" id=\"15575054\">15575054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;A Randomized, Placebo-Controlled Trial of Propafenone in the Prophylaxis of Paroxysmal Supraventricular Tachycardia and Paroxysmal Atrial Fibrillation. UK Propafenone PSVT Study Group,&rdquo; <i>Circulation</i>, 1995, 92(9):2550-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/7586356/pubmed\" target=\"_blank\" id=\"7586356\">7586356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boriani G, Capucci A, Lenzi T, et al, &ldquo;Propafenone for Conversion of Recent-Onset Atrial Fibrillation. A Controlled Comparison Between Oral Loading Dose and Intravenous Administration,&rdquo; <i>Chest</i>, 1995, 108(2):355-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/7634866/pubmed\" target=\"_blank\" id=\"7634866\">7634866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boriani G, Biffi M, Capucci A, et al, &ldquo;Oral Propafenone to Convert Recent-Onset Atrial Fibrillation in Patients With and Without Underlying Heart Disease. A Randomized, Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1997, 126(8):621-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/9103129/pubmed\" target=\"_blank\" id=\"9103129\">9103129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burgess E, Duff H, Wilkes P. Propafenone disposition in renal insufficiency and renal failure. <i>J Clin Pharmacol</i>. 1989;29(2):112-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/2715367/pubmed\" target=\"_blank\" id=\"2715367\">2715367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burgess ED, Duff HJ. Hemodialysis removal of propafenone. <i>Pharmacotherapy</i>. 1989;9(5):331-333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/2813154/pubmed\" target=\"_blank\" id=\"2813154\">2813154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo; <i>N Engl J Med</i>, 1991, 324(12):781-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/1900101/pubmed\" target=\"_blank\" id=\"1900101\">1900101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197. doi: 10.1093/eurheartj/ehr218.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fromm MF, Botsch S, Heinkele G, et al. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. <i>Eur J Clin Pharmacol</i>. 1995;48(3-4):279-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/7589055/pubmed\" target=\"_blank\" id=\"7589055\">7589055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funck-Brentano C, Kroemer HK, Lee JT, et al, &ldquo;Propafenone,&rdquo; <i>N Engl J Med</i>, 1990, 322(8):518-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/2405273/pubmed\" target=\"_blank\" id=\"2405273\">2405273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hii JT, Wyse DG, Gillis AM, et al, &ldquo;Propafenone-Induced Torsade de Pointes: Cross-Reactivity With Quinidine,&rdquo; <i>Pacing Clin Electrophysiol</i>, 1991,14(11 Pt 1):1568-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/1721143/pubmed\" target=\"_blank\" id=\"1721143\">1721143</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Libardoni M, Piovan D, Busato E, Padrini R. Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk. <i>Br J Clin Pharmacol</i>. 1991;32(4):527-528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/1958453 /pubmed\" target=\"_blank\" id=\"1958453 \">1958453 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rythmol (propafenone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rythmol SR (propafenone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rythmol (propafenone) [product monograph]. St-Laurent, Quebec, Canada: BGP Pharma Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rythmol (propafenone) [product monograph]. Etobicoke, Ontario, Canada:BGP Pharma ULC; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sarubbi B, Ducceschi V, Briglia N, et al, &ldquo;Compared Effects of Sotalol, Flecainide and Propafenone on Ventricular Repolarization in Patients Free of Underlying Structural Heart Disease,&rdquo; <i>Int J Cardiol</i>, 1998, 66(2):157-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/9829329/pubmed\" target=\"_blank\" id=\"9829329\">9829329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seto W, Trope AE, Gow RM. Propafenone disposition during continuous venovenous hemofiltration. <i>Ann Pharmacother</i>. 1999;33(9):957-959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/10492500/pubmed\" target=\"_blank\" id=\"10492500\">10492500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddoway LA, Roden DM, and Woosley RL, &ldquo;Clinical Pharmacology of Propafenone: Pharmacokinetics, Metabolism and Concentration-Response Relations,&rdquo; <i>Am J CArdiol</i>, 1984, 54(9):9D-12D.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/6496371/pubmed\" target=\"_blank\" id=\"6496371\">6496371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propafenone-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9821 Version 166.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709354\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F214329\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F214330\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F214373\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F214334\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F214335\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13657360\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F214336\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F214307\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F214292\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F29118606\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F214311\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F214310\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744558\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F214299\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F214314\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F214296\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F214366\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F214301\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F214327\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F214303\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F214317\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20619290\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F214305\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F214295\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F214313\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F214316\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F214319\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9821|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=propafenone-patient-drug-information\" class=\"drug drug_patient\">Propafenone: Patient drug information</a></li></ul></div></div>","javascript":null}